

Join Us On The Search For New Treatment For Lung Cancer

You May Be Eligible To Join Our Clinical Study, Researching A Biosimilar Study Treatment For Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

What Is This Study About?

- Phase III global clinical study
- evaluating the effectiveness and safety of a biosimilar study medication HD204 against the approved reference bevacizumab Avastin[®] given with chemotherapy for treating NSCLC
- approximately 592 participants across an estimated 20 countries globally

Who Is Eligible To Join?


AGE DIAGNOSIS

18+
Years

Metastatic Stage IV /
NSCLC Lung Cancer

What Is A Biosimilar?

- Essentially a similar version of an original biological medication (obtained via reverse-engineering)
- A patient can expect the same level of safety and effectiveness as taking the original biological treatment medication
- The study medication HD204 is a biosimilar of the reference bevacizumab Avastin®



Key Potential Benefits From Joining:



✓ PROFESSIONAL MEDICAL CARE

NO COST INVOLVED

▼ CONTINUAL
 TREATMENT

You will receive only either the study biosimilar HD204 or reference medication Avastin® Same professional level of medical care for all participants

All study medication, tests and medical care related to study is provided You have the option to continue treatment with HD2O4, if you are still benefiting from the therapies at end of study

What Is My Involvement In The Study?



Study centre visits every 3 weeks for up to 17 times



Receive chemotherapy up to 6 times within 1st 6 visits



Tumor assessment up to 6 times via CT or MRI scans



Physical exams, blood tests and other requirements as discussed with study doctor

If you have any concerns/questions on the study benefits, risks and responsibilities, feel free to discuss with us before or during the study.



Interested To Find Out More?

For more information, or if you wish to participate in this clinical study, please contact our study team today.

Clinical Research Centre, Hospital Raja Perempuan Zainab II Tel: +609-7452636